FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:191-198 July 20, 2000 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Recent research results suggest that the risk of breast cancer can be reduced. In this review I will focus on chemoprevention, emphasizing evidence from randomized clinical trials, and in addition summarize the evidence regarding preventive strategies involving surgery and lifestyle changes (Table 1).

View this table: [in this window] [in a new window]   Table 1. Potential Strategies for Reducing the Risk of Breast Cancer.

 
Chemoprevention

Tamoxifen and Risk Reduction

The risk of breast cancer is related to levels of endogenous^1,2 and exogenous^3,4,5 hormones. Tamoxifen and raloxifene, which are selective estrogen-receptor modulators, can be used to test the hypothesis that the risk of breast cancer can be reduced by estrogen antagonists.⁶

Tamoxifen is active against advanced . . . [Full Text of this Article]

Side Effects of Tamoxifen

Raloxifene and Risk Reduction

Side Effects of Raloxifene

Fenretinide and Risk Reduction

Prophylactic Surgery

Bilateral Mastectomy

Bilateral Oophorectomy

Future Approaches

Lifestyle and Risk Reduction

Environmental Factors

Conclusions

Source Information

From the Harbor–UCLA Research and Education Institute, Torrance, Calif.

Address reprint requests to Dr. Chlebowski at Harbor–UCLA Medical Center, 1124 W. Carson St., Bldg. J-3, Torrance, CA 90502, or at rchlebow@whi.org.

References

This article has been cited by other articles:

• Unterholzner, S., Willhauck, M. J., Cengic, N., Schutz, M., Goke, B., Morris, J. C., Spitzweg, C. (2006). Dexamethasone Stimulation of Retinoic Acid-Induced Sodium Iodide Symporter Expression and Cytotoxicity of 131-I in Breast Cancer Cells. J. Clin. Endocrinol. Metab. 91: 69-78 [Abstract] [Full Text]  
• Chlebowski, R. T., Chen, Z., Anderson, G. L., Rohan, T., Aragaki, A., Lane, D., Dolan, N. C., Paskett, E. D., McTiernan, A., Hubbell, F. A., Adams-Campbell, L. L., Prentice, R. (2005). Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. JNCI J Natl Cancer Inst 97: 439-448 [Abstract] [Full Text]  
• Knostman, K. A. B., Cho, J.-Y., Ryu, K.-Y., Lin, X., McCubrey, J. A., Hla, T., Liu, C. H., Di Carlo, E., Keri, R., Zhang, M., Hwang, D. Y., Kisseberth, W. C., Capen, C. C., Jhiang, S. M. (2004). Signaling through 3',5'-Cyclic Adenosine Monophosphate and Phosphoinositide-3 Kinase Induces Sodium/Iodide Symporter Expression in Breast Cancer. J. Clin. Endocrinol. Metab. 89: 5196-5203 [Abstract] [Full Text]  
• McTiernan, A., Tworoger, S. S., Rajan, K. B., Yasui, Y., Sorenson, B., Ulrich, C. M., Chubak, J., Stanczyk, F. Z., Bowen, D., Irwin, M. L., Rudolph, R. E., Potter, J. D., Schwartz, R. S. (2004). Effect of Exercise on Serum Androgens in Postmenopausal Women: A 12-Month Randomized Clinical Trial. Cancer Epidemiol. Biomarkers Prev. 13: 1099-1105 [Abstract] [Full Text]  
• McTiernan, A., Tworoger, S. S., Ulrich, C. M., Yasui, Y., Irwin, M. L., Rajan, K. B., Sorensen, B., Rudolph, R. E., Bowen, D., Stanczyk, F. Z., Potter, J. D., Schwartz, R. S. (2004). Effect of Exercise on Serum Estrogens in Postmenopausal Women: A 12-Month Randomized Clinical Trial. Cancer Res. 64: 2923-2928 [Abstract] [Full Text]  
• Pichert, G., Bolliger, B., Buser, K., Pagani, O. (2003). Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol 14: 9-19 [Abstract] [Full Text]  
• Col, N. F., Goldberg, R. J., Orr, R. K., Erban, J. K., Fortin, J. M., Chlebowski, R. T. (2002). Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model. Med Decis Making 22: 386-393 [Abstract]  
• Chlebowski, R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G. III, Burstein, H. J., Eisen, A., Lipkus, I., Pfister, D. G. (2002). American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. JCO 20: 3328-3343 [Abstract] [Full Text]  
• Ernst, T., Chang, L., Cooray, D., Salvador, C., Jovicich, J., Walot, I., Boone, K., Chlebowski, R. (2002). The Effects of Tamoxifen and Estrogen on Brain Metabolism in Elderly Women. JNCI J Natl Cancer Inst 94: 592-597 [Abstract] [Full Text]  
• Green, J. E., Shibata, M.-A., Shibata, E., Moon, R. C., Anver, M. R., Kelloff, G., Lubet, R. (2001). 2-Difluoromethylornithine and Dehydroepiandrosterone Inhibit Mammary Tumor Progression but not Mammary or Prostate Tumor Initiation in C3(1)/SV40 T/t-antigen Transgenic Mice. Cancer Res. 61: 7449-7455 [Abstract] [Full Text]  
• Hogle, L. F. (2001). Chemoprevention for Healthy Women: Harbinger of Things to Come?. Health (London) 5: 311-333 [Abstract]  
• Levine, M., Moutquin, J.-M., Walton, R., Feightner, J. (2001). Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 164: 1681-1690 [Abstract] [Full Text]